Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, ...

Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Shares in French pharma major Sanofi were 6% lower late Thursday after the presentation of the company’s second quarter ...

This study could potentially impact the stock performance of Regeneron Pharmaceuticals and Sanofi, as positive results may enhance investor sentiment and market valuation. The study’s focus on COPD, a ...

Inhalable Biologics Market Explosive 16.2% CAGR forecast for inhalable biologics market, fueled by innovation and patient demand for non-in ...

Sanofi is already a major player in the ASD market with its big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab), and the company has previously highlighted amlitelimab as one of a dozen ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is currently approved as an add-on treatment for moderate-to-severe asthma characterised by an eosinophilic phenotype – a specific form of ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Appraisal of Dupilumab for treating moderate to severe chronic obstructive pulmonary disease [ID6235] 6.1. Introduction by the Chair, Radha Todd - Part 1 only (open session) 6.2. Declaration of ...